Q2 2026 earnings put Humacyte stock back in focus

Humacyte (HUMA) has moved back into the spotlight after reporting second quarter 2026 results, with modest revenue and a sizeable quarterly loss prompting investors to reassess the stock’s risk and potential.

The Q2 2026 loss, the recent Nasdaq minimum bid price notice and the interim Phase III dialysis data have all landed against a weak backdrop for Humacyte. The stock has a 1 day share price return of down 6.34% and a 90 day share price return of down 33.50%, while the 1 year total shareholder return is down 62.64%. This indicates that momentum has been fading despite pockets of positive trial news.

If Humacyte’s story has you reassessing high risk biotech exposure, this can be a useful moment to widen the lens and look at other healthcare related ideas through the 43 healthcare AI stocks

Humacyte now trades at a steep discount to the average analyst price target, even after the Phase III update and Nasdaq warning. Is the market applying a reasonable safety buffer, or is it marking the stock down too far?

Most Popular Narrative: 83.4% Undervalued

With Humacyte’s last close at $0.67 against a narrative fair value of $4.00, the gap between price and expectations is wide enough to draw attention.

Positive Phase III results for the ATEV in dialysis access, targeting women and high risk men who represent more than half of the dialysis population, align with a large, chronically treated patient group that could influence longer term revenue and earnings if an added indication is approved.

Want to see what kind of revenue curve and profit profile would need to sit behind that dialysis focus. The narrative leans on aggressive growth, margin expansion and a rich future earnings multiple that is usually reserved for far larger companies.

Result: Fair Value of $4.00 (UNDERVALUED)

However, Humacyte still carries real execution risk, including high cash use relative to modest US$2.0 million revenue and the possibility that dialysis or trauma uptake falls short of bullish expectations.

Another View on Humacyte’s Valuation

The fair value of $4.00 for Humacyte rests on optimistic analyst forecasts. Yet Humacyte currently trades on a P/B of 15.4x compared with about 2x for peers and 2.5x for the wider US biotechs industry, which signals a rich price tag. How comfortable are you paying such a premium for a company with US$2.0 million in revenue and ongoing losses?

Next Steps

With both risks and rewards in play for Humacyte, the next move is not obvious. Look through the details yourself and weigh the 1 key reward and 3 important warning signs

Looking for more investment ideas beyond Humacyte?

If Humacyte has sharpened your focus on risk and reward, you may want to broaden your watchlist with fresh ideas that match your preferred balance of upside, income and resilience.

• Target potential mispricing by scanning a focused set of companies that screen as 49 high quality undervalued stocks.
• Strengthen your portfolio’s foundation with businesses appearing in the solid balance sheet and fundamentals stocks screener (49 results).
• Hunt for future standouts before the crowd pays attention by reviewing the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.